This site is intended for Great Britain healthcare professionals only 

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Menu

Close

AboutAboutHow Cibinqo worksIntroducing CibinqoMOA OverviewPatient ProfilesPatient Profiles OverviewPatient Profile 1Patient Profile 2Patient Profile 3Patient Profile 4EfficacyEfficacyClinical EfficacyStudy OverviewJADE COMPAREJADE MONOJADE REGIMENJADE TEENJADE EXTENDSafety
Safety
 
Safety
 
Safety Guidance
DosingDosingDosingOral once-daily dosingPractical ConsiderationsSupport & ResourcesSupport & ResourcesHCP ResourcesMedicine Evidence InformationPatient ResourcesVideos
Materials

Information on how to access Cibinqo® (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

JADE TEENEvaluating the efficacy and safety of Cibinqo in adolescent patients aged 12–171,2​​​​​​​

This pivotal Phase III clinical trial evaluated the efficacy and safety of Cibinqo in combination with medicated topical therapy versus placebo in 285 adolescent patients age 12–17 years with moderate-to-severe AD.2

STUDY DESIGN2

*Patients not eligible for JADE EXTEND entered the 4-week off-treatment follow-up period.
Patients used non-medicated emollient at least twice a day and medicated topical therapy such as corticosteroids, calcineurin inhibitors, or PDE4 inhibitors, as per protocol guidance, to treat active lesions during the study.

Co-primary endpoints:
  • IGA response (0/1 with a ≥2-grade improvement) at Week 12 vs placebo
  • EASI-75 response at Week 12 vs placebo
Key secondary endpoints:
  • PP-NRS4 improvement at Weeks 2, 4 and 12
  • Change from baseline in PSAAD at Week 12

Baseline characteristics2
Scroll left to view table

No. (%)


Cibinqo

Placebo (N=96) 100 mg (N=95) 200 mg (N=94)  
All
(N=285)

Age, median (IQR), y 14.0 (13.5–16.5) 16.0 (14.0–17.0) 15.0 (13.0–16.0) 15.0 (13.0–17.0)
Age group, y
• 12–17*
•  ≥18
 
​​​​​​​• 95 (99.0)
​​​​​​​• 1 (1.0)

 
​​​​​​​• 95 (100.0)
​​​​​​​• 0

 
• 94 (100.0)
​​​​​​​• 0

 
• 284 (99.6)
​​​​​​​• 1 (0.4)

Female 52 (54.2) 50 (52.6) 38 (40.4) 140 (49.1)
Male 44 (45.8) 45 (47.4) 56 (59.6) 145 (50.9)
Race, n (%)
• White
• Asian
 Black or African American
 Multiracial​​​​​​​
• Other
​​​​​​​
• Not reported
 
​​​​​​​• 56 (58.3)
• 32 (33.3)
• 3 (3.1)
• 1 (1.0)
• 2 (2.0)
​​​​​​​• 2 (2.1)

 
​​​​​​​• 52 (54.7)
• 31 (32.6)
• 9 (9.5)
• 0
​​​​​​​• 3 (3.2)
 0
 
​​​​​​​• 52 (55.3)
• 31 (33.0)
• 5 (5.3)
• 1 (1.1)
• 5 (5.4)
​​​​​​​• 0

 
​​​​​​​• 160 (56.1)
• 94 (33.0)
• 17 (6.0)
• 2 (0.7)
• 10 (3.5)
​​​​​​​• 2 (0.7)

Ethnicity, n (%)
• Not Hispanic or Latino
• Hispanic or Latino
• Not reported
 
​​​​​​​• 65 (67.7)
• 25 (26.0)
• 6 (6.3)

 
• 63 (66.3)
• 26 (27.4)
​​​​​​​• 6 (6.3)

 
• 69 (73.4)
​​​​​​​• 25 (26.6)
​​​​​​​• 0

 
​​​​​​​•197 (69.1)
• 76 (26.7)
• 12 (4.2)

Disease duration, mean (SD), y 10.5 (4.8) 9.8 (5.4) 9.7 (5.3) 10.0 (5.2)
Prior medication for AD§
• Any prior medication
• Topical agents alone
• Systemic ± topical agents#
• Dupilumab
 
• 95 (99.0)
• 71 (74.0)
• 24 (25.0)
​​​​​​​• 1 (1.0)

 
• 95 (100.0)
• 68 (71.6)
• 27 (28.4)
​​​​​​​• 1 (1.1)

 
• 92 (97.9)
• 70 (74.5)
• 22 (23.4)
​​​​​​​• 1 (1.1)

 
• 282 (98.9)
• 209 (73.3)
• 73 (25.6)
​​​​​​​• 3 (1.1)

IGA score
• 3
• 4
 
• 57 (59.4)
​​​​​​​• 39 (40.6)

 
• 57 (60.0)
​​​​​​​• 38 (40.0)

 
• 61 (64.9)
​​​​​​​• 33 (35.1)

 
• 175 (61.4)
​​​​​​​• 110 (38.6)

EASI score, mean (SD) 29.2 (12.7) 31.0 (12.8) 29.5 (12.2) 29.9 (12.5)
BSA affected, mean (SD), % 45.8 (22.4) 51.2 (21.7) 48.7 (21.7) 48.6 (22.0)
PP-NRS total score 7.2 (1.7) 7.0 (1.8) 6.8 (2.0) ​​​​​7.0 (1.8)
PSAAD
• No. of patients
• Total score, mean (SD)​​​​​​​
 
• 95
​​​​​​​• 5.0 (2.4)

 
• 95
​​​​​​​• 4.9 (2.1)

 
• 93
​​​​​​​• 4.8 (2.3)

 
• 283
​​​​​​​• 4.9 (2.3)

SCORAD
• No. of patients
• Total score, mean (SD)​​​​​​​
 
​​​​​​​• 96
​​​​​​​• 68.5 (13.4)

 
• 95
​​​​​​​• 67.6 (13.5)

 
​​​​​​​• 93
​​​​​​​• 66.2 (13.3)

 
​​​​​​​• 284
​​​​​​​• 67.5 (13.4)

SCORAD Sleep Loss VAS
• No. of patients
• Total score, mean (SD)​​​​​​​
 
• 96
​​​​​​​• 5.7 (2.9)

 
• 95
​​​​​​​• 5.3 (2.9)

 
• 93
​​​​​​​• 5.6 (2.9)

 
• 284
​​​​​​​• 5.5 (2.9)

CDLQI
​​​​​​​
• No. of patients
• Total score, mean (SD)
 
​​​​​​​• 96
​​​​​​​• 14.0 (6.7)

 
​​​​​​​• 95 
 14.3 (6.1)
 
​​​​​​​• 94
 13.6 (7.0)
 
​​​​​​​• 285
 14.0 (6.6)
POEM
• No. of patients
• Total score, mean (SD)​​​​​​​
 
​​​​​​​• 95
• 19.8 (5.9)

 
• 95
​​​​​​​• 19.5 (6.4)

 
• 94
​​​​​​​• 19.2 (6.2)

 
• 284
​​​​​​​• 19.5 (6.2)

*One patient in the Cibinqo 200 mg group was age 11 years at the time of consent to participate in the study, which was a protocol deviation.
​​​​​​​One patient in the placebo group was enrolled at age 18 years, which was a protocol deviation.
Includes patients who identified as American Indian or Alaskan native and native Hawaiian or Pacific Islander.
§Patients were counted once for each main category (i.e., topical agents or systemic agents) in an exclusive manner.
Topical agents included corticosteroids, calcineurin inhibitors, and crisaborole.
#Systemic agents included corticosteroids, cyclosporin, nonbiologic agents, and biologic agents.

Inclusion/exclusion criteria2INCLUSION CRITERIA2
  • 12 to <18 years of age
  • Clinically diagnosed with chronic AD, confirmed by the Hanifin and Rajka criteria of AD at the screening and baseline visits
  • Criteria for AD diagnosis include ≥3 of the basic features of pruritus: typical morphology and distribution, including flexural lichenification or linearity in adults and facial and extensor involvement in infants and children; chronic or chronically relapsing dermatitis; and personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis); along with ≥3 of 23 minor features specified in the criteria
  • Have a documented history of inadequate response to treatment with topical medications or a candidate for systemic therapies
  • Moderate to severe AD defined as BSA ≥10%, IGA ≥3, EASI ≥16, and PP-NRS ≥4 at the baseline visit
  • Body weight ≥25 kg
EXCLUSION CRITERIA2
  • Active forms of other inflammatory skin diseases
  • Prior treatment with any systemic JAK inhibitors
  • Vaccination with, or exposure to, a live or attenuated vaccine within 6 weeks prior to the first dose
  • Participation in other clinical studies involving investigational drug(s) within 8 weeks prior to study entry
  • Uncontrolled, clinically significant laboratory abnormality that could affect study interpretation
  • Any major psychiatric condition
  • Unwillingness to discontinue current AD medications prior to the study
  • Requiring treatment with prohibited medications during the study
  • Medical history of thrombocytopenia, coagulopathy or platelet dysfunction
  • Presence or history of certain infections, cancers, lymphoproliferative disorders, and other medical conditions at the discretion of the investigator
  • Pregnant or breastfeeding women
  • Women of childbearing potential who are unwilling to use contraception
PRIMARY ENDPOINT – SKIN CLEARANCESignificantly more patients achieved skin clearance with Cibinqo vs placebo1,2​​​​​​​

In 12 weeks, 68.5% of adolescent patients treated with Cibinqo 100 mg achieved EASI-75 vs 41.5% with placebo (P<0.05).1–3

Proportion of patients achieving EASI-75 (in combination with medicated topical therapy)1–3
Scroll left to view table
EASI-75 at Week 12 no./Total no. (%, 95% CI)
Cibinqo 200 mg 67/93 (72.0%; 62.9–81.2)
Cibinqo 100 mg 61/89 (68.5%; 58.9–78.2)
Placebo 39/94 (41.5%; 31.5–51.4)

The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily.

In 12 weeks, 41.6% of adolescent patients treated with Cibinqo 100 mg achieved IGA 0/1 vs 24.5% with placebo (P<0.05).1–3

Proportion of patients achieving IGA 0/1 at 12 weeks (in combination with medicated topical therapy)1–3
Scroll left to view table
IGA 0/1 at Week 12 no./Total no. (%, 95% CI)
Cibinqo 200 mg 43/93 (46.2%; 36.1–56.4)
Cibinqo 100 mg 37/89 (41.6%; 31.3–51.8)
Placebo 37/89 (41.6%; 31.3–51.8)
The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily.KEY SECONDARY ENDPOINT – ITCH REDUCTIONItch relieved with Cibinqo in adolescents1,2

After 2 weeks, 27.2% of adolescent patients treated with Cibinqo 100 mg achieved PP-NRS4 vs 12.6% with placebo (P=0.0119).1,2

Proportion of patients achieving PP-NRS4 (in combination with medicated topical therapy)1–3​​​​​​​
Scroll left to view table
PP-NRS4 at Week 12 no./Total no. (%, 95% CI)
Cibinqo 200 mg 41/74 (55.4%; 44.1–66.7)
Cibinqo 100 mg 40/76 (52.6%; 41.4–63.9)
Placebo 25/84 (29.8%; 20.0–39.5)

The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily.

Explore moreSafety

3,128 patients were treated with Cibinqo in clinical studies in AD representing 2,089 patient-years of exposure.1

View safety guidanceLoading
  • References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics.

Dosing

Learn more about flexible dosing in patients on Cibinqo.

Discover oral once-daily dosingLoading

AD=atopic dermatitis; BSA=body surface area; CDLQI=Children's Dermatology Life Quality Index; CI=confidence interval; EASI=Eczema Area and Severity Index; IGA=Investigator’s Global Assessment; IQR=interquartile range; JAK=Janus kinase; NS=not significant; PDE4=Type 4 cyclic nucleotide phosphodiesterase; POEM=Patient-Oriented Eczema Measure; PP-NRS=Peak Pruritus Numerical Rating Scale; PSAAD=Pruritus and Symptoms Assessment for Atopic Dermatitis; SCORAD=SCORing Atopic Dermatitis; SD=standard deviation; VAS=Visual Analog Scale.

Prescribing information:
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.

References:

Cibinqo (abrocitinib) Summary of Product Characteristics.Eichenfield L, et al. JAMA Dermatol 2021; doi: 10.1001/jamadermatol.2021.2830. Eichenfield L, et al. JAMA Dermatol 2021; doi:10.1001/jamadermatol.2021.2830. Supplementary appendix 3.
PP-CIB-GBR-0065. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-PFE-GBR-3849. November 2021

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?

You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​